Stochastic modeling of drug resistance in cancer

Journal of Theoretical Biology

Volumn 239, Issue 3, 2006, Pages 351-366

  Komarova, Natalia ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Mathematical model; Multi drug therapy; Pre existence; Targeted drugs; Treatment success

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER;

ARTICLE; CANCER; CANCER CELL; CANCER GROWTH; HUMAN; MATHEMATICAL MODEL; MUTATION RATE; PRIORITY JOURNAL; STOCHASTIC MODEL; TREATMENT OUTCOME; TUMOR VOLUME; TURNOVER TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; STOCHASTIC PROCESSES; TREATMENT OUTCOME;

EID: 33644931688     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2005.08.003     Document Type: Article

References (42)

1. D.E. Axelrod, K.A. Baggerly, and M. Kimmel Gene amplification by unequal sister chromatid exchange probabilistic modeling and analysis of drug resistance data J. Theor. Biol. 168 2 1994 151 159
2. S. Bonhoeffer, H. Mohri, D. Ho, and A.S. Perelson Quantification of cell turnover kinetics using 5-bromo- 2′-deoxyuridine J. Immunol. 164 10 2000 5049 5054
3. P.C. Brown, S.M. Beverley, and R.T. Schimke Relationship of amplified dihydrofolate reductase genes to double minute chromosomes in unstably resistant mouse fibroblast cell lines Mol. Cell. Biol. 1 12 1981 1077 1083
4. H.M. Byrne, and M.A. Chaplain Growth of nonnecrotic tumors in the presence and absence of inhibitors Math. Biosci. 130 2 1995 151 181
5. G.K. Chen, G.E. Duran, A. Mangili, L. Beketic-Oreskovic, and B.I. Sikic MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells Br. J. Cancer 83 7 2000 892 898
6. L. Cojocaru, and Z. Agur A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs Math. Biosci. 109 1 1992 85 97
7. A.J. Coldman, and J.H. Goldie Role of mathematical modeling in protocol formulation in cancer chemotherapy Cancer Treat. Rep. 69 10 1985 1041 1048
8. A.J. Coldman, and J.H. Goldie A stochastic model for the origin and treatment of tumors containing drug-resistant cells Bull. Math. Biol. 48 3-4 1986 279 292
9. A.J. Coldman, and J.M. Murray Optimal control for a stochastic model of cancer chemotherapy Math. Biosci. 168 2 2000 187 200
10. E.A. Gaffney The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling J. Math. Biol. 48 4 2004 375 422
11. E.A. Gaffney The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics Bull. Math. Biol. 67 3 2005 563 611
12. S.N. Gardner, and M. Fernandes New tools for cancer chemotherapy computational assistance for tailoring treatments Mol. Cancer Ther. 2 10 2003 1079 1084
13. J.H. Goldie, and A.J. Coldman A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat. Rep. 63 11-12 1979 1727 1733
14. J.H. Goldie, and A.J. Coldman A model for resistance of tumor cells to cancer chemotherapeutic agents Math. Biosci. 65 1983 291 307
15. J.H. Goldie, and A.J. Coldman Quantitative model for multiple levels of drug resistance in clinical tumors Cancer Treat. Rep. 67 10 1983 923 931
16. J.H. Goldie, and A.J. Coldman A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses Cancer Invest. 3 6 1985 553 564
17. J.H. Goldie, and A.J. Coldman Drug Resistance in Cancer Mechanisms and Models 1998 Cambridge University Press Cambridge
18. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, and C.L. Sawyers Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 5531 2001 876 880
19. L.E. Harnevo, and Z. Agur The dynamics of gene amplification described as a multitype compartmental model and as a branching process Math. Biosci. 103 1 1991 115 138
20. L.E. Harnevo, and Z. Agur Use of mathematical models for understanding the dynamics of gene amplification Mutat. Res. 292 1 1993 17 24
21. Y. Iwasa, F. Michor, and M.A. Nowak Stochastic tunnels in evolutionary dynamics Genetics 166 3 2004 1571 1579
22. T.L. Jackson, and H.M. Byrne A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy Math. Biosci. 164 1 2000 17 38
23. J.P. Jaffrezou, G. Chen, G.E. Duran, J.S. Kuhl, and B.I. Sikic Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis J. Natl Cancer Inst. 86 15 1994 1152 1158
24. R.J. Kaufman, P.C. Brown, and R.T. Schimke Loss and stabilization of amplified dihydrofolate reductase genes in mouse sarcoma S-180 cell lines Mol. Cell. Biol. 1 12 1981 1084 1093
25. W.S. Kendal, and P. Frost Pitfalls and practice of Luria-Delbruck fluctuation analysis a review Cancer Res. 48 5 1988 1060 1065
26. M. Kimmel, and D.E. Axelrod Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity Genetics 125 3 1990 633 644
27. M. Kimmel, and D.N. Stivers Time-continuous branching walk models of unstable gene amplification Bull. Math. Biol. 56 2 1994 337 357
28. M. Kimmel, A. Swierniak, and A. Polanski Infinite-dimensional model of evolution of drug resistance of cancer cells J. Math. Syst. Est. Control 8 1998 1 16
29. L.A. Loeb, C.F. Springgate, and N. Battula Errors in DNA replication as a basis of malignant changes Cancer Res. 34 9 1974 2311 2321
30. F. McCormick New-age drug meets resistance Nature 412 6844 2001 281 282
31. R.G. McKinnell, R.E. Parchment, A.O. Perantoni, and G.B. Pierce The Biological Basis of Cancer 1998 Cambridge University Press Cambridge
32. S.H. Moolgavkar, A. Dewanji, and D.J. Venzon A stochastic two-stage model for cancer risk assessment. I. The hazard function and the probability of tumor Risk Anal. 8 3 1988 383 392
33. J.M. Murray, and A.J. Coldman The effect of heterogeneity on optimal regimens in cancer chemotherapy Math. Biosci. 185 1 2003 73 87
34. E. Parzen Stochastic Processes 1999 Society for Industrial and Applied Mathematics Philadelphia
35. F.M.J. Schabel, M.W. Trader, W.R.J. Laster, T.H. Corbett, and D.P.J. Griswold cis-Dichlorodiammineplatinum(II) combination chemotherapy and cross-resistance studies with tumors of mice Cancer Treat. Rep. 63 9-10 1979 1459 1473
36. F.M.J. Schabel, H.E. Skipper, M.W. Trader, W.R.J. Laster, D.P.J. Griswold, and T.H. Corbett Establishment of cross-resistance profiles for new agents Cancer Treat. Rep. 67 10 1983 905 922
37. J. Smieja, and A. Swierniak Different models of chemotherapy taking into account drug resistance stemming from gene amplification Int. J. Appl. Math. Comput. Sci. 13 3 2003 297 305
38. G.W. Swan Role of optimal control theory in cancer chemotherapy Math. Biosci. 101 2 1990 237 284
39. A. Swierniak, and J. Smieja Cancer chemotherapy optimization under evolving drug resistance Nonlinear Anal. 47 2001 375 386
40. A.J. Tipping, F.X. Mahon, V. Lagarde, J.M. Goldman, and J.V. Melo Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells Blood 98 13 2001 3864 3867
41. T.D. Tlsty, B.H. Margolin, and K. Lum Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis Proc. Natl Acad. Sci. USA 86 23 1989 9441 9445
42. T.E. Wheldon Mathematical Models in Cancer Research 1988 Adam Hilger Bristol